Nicox

Nicox, an international ophthalmic R&D company, has been dedicated to maintaining vision and improving ocular health since its establishment in 1996. With a focus on biotechnology, healthcare, and medical devices, the company is committed to building a diversified portfolio of therapeutic products to meet the needs of eyecare practitioners and patients globally. Nicox's global growth strategy revolves around outstanding international collaborations and its proprietary programs, including those from its nitric oxide-donating research platform. The most recent development for Nicox took place on July 18, 2024, with a €3.30M Post-IPO Equity investment. This investment, although not disclosed with specific investors, signifies a potential milestone for the company. The headquarter of Nicox is located in France. For further information, individuals can visit their website at www.nicox.com.